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Glyburide [International Nonproprietary Name (INN), glibenclamide] is a second-generation sulfonylurea drug that is used to treat type II diabetes mellitus. This drug is extensively metabolized; the 4-hydroxy metabolite predominates, with lesser amounts of the 3-hydroxy metabolite, and a small amount (Ͻ2% of dose) of an unidentified metabolite (Brian, 2000) . CYP2C9 is primarily responsible for the metabolism of glyburide (Miners and Birkett, 1998; Brian, 2000) .
An extensive literature review shows that most of the published drug interactions for glyburide describe the effect of a concomitant drug on the hypoglycemic activity of glyburide, leading to hypoglycemia. For example, cotrimoxazole (Asplund et al., 1983) , cimetidine (Kubacka et al., 1987) , miconazole (Loupi et al., 1982) , fluconazole (Albengres et al., 1998) , and gemfibrozil (Ahmad, 1991) , which are all CYP2C9 inhibitors, inhibit the pharmacokinetics and clinical effect of glyburide.
Conversely, some authors have observed that glyburide inhibited the metabolism of coadministered drugs with a consequent risk of toxic phenomena (Jassel, 1991; Islam et al., 1996) . However, there are no available data on the inhibitory effect of glyburide on drugmetabolizing enzymes, especially P450 1 isoforms. This study assessed the potential of glyburide to inhibit different P450 isoforms in vitro using human liver microsomes and to examine the mechanism of the interaction of glyburide with coadministered drugs.
Materials and Methods
Materials. Glyburide, phenacetin, acetaminophen, chlorzoxazone, paclitaxel, dextromethorphan, dextrorphan, furafylline, NADP, EDTA, MgCl 2 , glucose 6-phosphate, and glucose-6-phosphate dehydrogenase were purchased from Sigma-Aldrich (St. Louis, MO). 1-Hydroxymidazolam, S-warfarin, 7-hydroxywarfarin, S-mephenytoin, 6␣-hydroxypaclitaxel, and 4Ј-hydroxymephenytoin were obtained from Ultrafine Chemical Co. (Manchester, UK). Acetonitrile and methanol were acquired from Fisher Scientific Co. (Pittsburgh, PA), and Bukwang Pharmaceutical Co. (Seoul, Korea) kindly provided midazolam. All other reagents and chemicals were of analytical or high-performance liquid chromatography (HPLC) grade. Pooled human liver microsomes were obtained from BD Gentest Corp. (Woburn, MA).
Incubation Studies. All incubations were performed in duplicate, and the mean values were used for analysis. Briefly, each incubation was performed with 1 mg/ml human liver microsomes in a final incubation volume of 0.25 ml. The incubation medium contained 100 mM phosphate buffer (pH 7.4) containing an NADPH-regenerating system (including 1.3 mM NADP, 3.3 mM glucose 6-phosphate, 3.3 mM MgCl 2 , and 1.0 U/ml glucose-6-phosphate dehydrogenase). The incubation mixture containing glyburide (final concentration 1-100 M) was preincubated for 5 min. To determine whether the inhibition of P450 isoforms by glyburide is mechanism-based, glyburide was preincubated with the incubation medium at 37°C for 5 to 15 min, either in the presence or absence of the NADPH-regenerating system. After preincubation, probe substrates were added either with or without the NADPH-regenerating system. The incubation conditions including incubation times, microsome concentrations, and probe substrate concentrations have been reported elsewhere (Bourrie et al., 1996; Shin et al., 1999 Shin et al., , 2002 . After incubation at 37°C for a specific period of time, the reaction was stopped by placing the incubation tubes on ice and adding 70 l of ice-cold acetonitrile or 10% perchloric acid depending on the reactions, as described previously (Bourrie et al., 1996; Shin et al., 1999 Shin et al., , 2002 ). The incubation mixtures were then centrifuged at 10,000g for 5 min at 4°C. Aliquots of the supernatant were injected onto an HPLC system. HPLC Analysis. HPLC assays for the respective products of the P450 marker reactions were performed. The reactions investigated were phenacetin O-deethylation for CYP1A2 (Tassaneeyakul et al., 1993) , S-warfarin 7-hydroxylation for CYP2C9 (Rettie et al., 1992) , S-mephenytoin 4Ј-hydroxylation for CYP2C19 (Wrighton et al., 1993) , dextromethorphan O-demethylation for CYP2D6 (Broly et al., 1989) , paclitaxel 6␣-hydroxylation for CYP2C8 (Harris et al., 1994) , and midazolam 1-hydroxylation for CYP3A4 (Thummel et al., 1994) . The incubation conditions and analytical assays for the activities of these isoforms were similar to the method previously described (Bourrie et al., 1996; Shin et al., 1999 Shin et al., , 2002 . The HPLC system consisted of a Shiseido SI-1 system (Shiseido Co., Tokyo, Japan) and a Jasco FP-2020 plus fluorescence detector (Jasco Co., Tokyo, Japan).
Data Analysis. The IC 50 values (concentration of the inhibitor causing 50% inhibition of the original enzyme activity) were determined graphically. The apparent inhibitory constants (K i ) were calculated using graphical analysis of secondary plots of the slopes of Lineweaver-Burk plots of glyburide versus probe drug-catalyzed metabolite formation using GraphPad Prism Software (GraphPad Software Inc., San Diego, CA).
Results
Glyburide strongly inhibited CYP2C9-catalyzed S-warfarin 7-hydroxylation with an apparent IC 50 of 11.3 M (Fig. 1) . The Lineweaver-Burk plots, Dixon plots, and secondary reciprocal plots indicated that glyburide competitively inhibited CYP2C9 activity, with an apparent K i of 2.4 M (Fig. 2) . To determine whether the inhibition by glyburide is substrate-specific, we examined the inhibitory effect of glyburide on CYP2C9-catalyzed phenytoin p-hydroxylation and found that glyburide inhibited it competitively with a K i (IC 50 ) value of 3.1 (9.4) M (Fig. 2.) . Glyburide showed weak inhibition on CYP3A4 with a competitive manner [K i (IC 50 ) ϭ 42.5 (90.0) M]. However, glyburide showed minimal or negligible inhibition of the other P450s tested (Fig. 1) . Preincubation of glyburide with an NADPH-regenerating system for 15 min before the addition of the specific substrates, to evaluate whether glyburide showed mechanism-based inhibition, did not increase the degree of inhibition (data not shown).
Discussion
Since the management of diabetes mellitus usually involves the treatment of concurrent pathologies, drug interactions with coadministered drugs should be considered when prescribing sulfonylurea drugs. Glyburide is reported to cause drug interactions with numerous drugs leading to an increase or decrease in the glyburide concentration, resulting in hypoglycemia or hyperglycemia (Asplund et al., 1983; Kubacka et al., 1987; Self et al., 1989; Ahmad, 1991) . Conversely, several studies have shown that glyburide inhibited coadministered drugs (Jassel, 1991; Islam et al., 1996) .
Of the P450-catalyzed reactions tested here, glyburide inhibited CYP2C9-catalyzed S-warfarin 7-hydroxylation most significantly, with a K i of 2.4 M. Although this effect is weaker than that of sulfaphenazole (K i Ͻ 1 M) (Rettie et al., 1992) , a known CYP2C9 inhibitor, it is more potent than any other CYP2C9 inhibitor, including tolbutamide (K i Ϸ 100 M) (Yamazaki and Shimada, 1997) , gemfibrozil (K i ϭ 5.8 M) (Wen et al., 2001 ), and fluconazole (K i ϭ 8 M) (Kunze et al., 1996) . Following the standard daily dose of glyburide (1.75-7 mg), the peak plasma concentrations of glyburide at a steady state, which show substantial interindividual variation, range from 88 to 680 ng/ml (approximately 0.2-1.4 M) (Jonsson et al., 2000) . Therefore, the K i of glyburide is approximately 1.5 to 6.5 times higher than its maximal concentration after administration of a typical dose.
Theoretically, drug interactions based on the inhibition of hepatic metabolism (FDV: fractional decrement in reaction velocity) can be calculated from the K i and the appropriate concentration of the inhibitor ([I]) of the metabolic enzyme in the liver using the following predictive model: FDV ϭ [I]/([I] ϩ K i ), assuming that the inhibitory pattern is competitive and that the substrate concentration is much less than the K m (von Moltke et al., 1998) . However, the in vivo concentration of the inhibitor near the metabolic enzyme is unknown, although glyburide is very highly lipophilic (Siluk et al., 2002) . Therefore, it is possible that, with long-term administration, glyburide accumulates in tissues, such as the liver, kidney, and brain. Although the exact liver/plasma partition coefficient is unknown, we expect glyburide to inhibit approximately 7 to 37% of the in vivo clearance of warfarin, a CYP2C9 substrate, if the peak plasma concentrations of Glyburide was incubated using the conditions described under Materials and Methods. The enzyme reactions evaluated were CYP1A2-catalyzed phenacetin O-de-ethylation (‚), CYP2C19-catalyzed S-mephenytoin 4-hydroxylation (OE), CYP2D6-catalyzed dextromethorphan O-demethylation (ƒ), CYP2E1-catalyzed chlorzoxazone 6-hydroxylation (), CYP3A4-catalyzed midazolam 1-hydroxylation (Ⅺ), CYP2C8-catalyzed paclitaxel 6␣-hydroxylation (f), CYP2C9-catalyzed S-warfarin 7-hydroxylation (E), and phenytoin p-hydroxylation (F). Each data point represents the average of duplicate experiments.
FIG. 2. The Lineweaver-Burk plots, Dixon plots, and secondary reciprocal plots indicated that glyburide competitively inhibited CYP2C9 activity.
Representative Dixon plots with 5 (E), 10 (F), and 25 (Ⅺ) M of S-warfarin (A) and phenytoin (D) with 10 (E), 25 (F), 50 (Ⅺ), and 100 (f) M in the absence or presence of glyburide (1, 5, 10, and 25 M). Representative Lineweaver-Burk plots of S-warfarin (B, 0 -25 M) and phenytoin (E, 0 -100 M) in the absence (f) or presence of 1 (‚), 5 (OE), 10 (E), and 25 (F) M glyburide. Secondary plots of the slopes taken from Lineweaver-Burk plots versus the glyburide concentration for S-warfarin (C) and phenytoin (F). Each data point represents the average of duplicate measurements. Glyburide was incubated using the conditions described under Materials and Methods.
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at ASPET Journals on September 6, 2017 dmd.aspetjournals.org glyburide are used in the scaling model described above. Although this predicted inhibitory effect of glyburide is not so potent, the above extrapolation formula does not consider hepatic drug uptake, protein binding, rates of elimination, or intrahepatic glyburide concentrations (von Moltke et al., 1998) . Considering these factors would increase the possibility of drug interactions.
There are no in vivo studies of the effect of glyburide on CYP2C9-catalyzed metabolism, but indirect clinical data support our in vitro findings, since glyburide has been shown to enhance the anticoagulant effect of warfarin, resulting in hypothrombinemia leading to death (Jassel, 1991) . Warfarin is a mixture of S-and R-forms. The metabolism of S-warfarin, the pharmacologically more active enantiomer, is catalyzed by CYP2C9, whereas the metabolism of R-warfarin is catalyzed by CYP1A2 and CYP3A4 (Kaminsky and Zhang, 1997; Yamazaki and Shimada, 1997) . Therefore, it is reasonable to postulate that the clinical interaction of glyburide and warfarin can be explained by inhibition of CYP2C9-mediated S-warfarin metabolism leading to elevated warfarin concentrations. Due to the lack of data, however, we could not confirm that glyburide also inhibits other CYP2C9 substrates. When we evaluated the effect of glyburide on the metabolism of phenytoin as a different CYP2C9 substrate (Bajpai et al., 1996; Shin et al., 2002) , we found its potent inhibition (K i ϭ 3.1 M) and similar inhibitory potency compared with that of warfarin (K i ϭ 2.4 M). Glyburide also inhibited CYP3A4-catalyzed midazolam 1-hydroxylation, but showed weak inhibition (K i ϭ 42.5 M); therefore, only minor drug interactions may be predicted. Islam et al. (1996) reported that the coadministration of cyclosporine, which is primarily metabolized by CYP3A4, with glyburide resulted in a 57% increase in the AUC of cyclosporine in kidney transplant patients. The authors suggested that this drug interaction was caused by the inhibition of CYP3A4-catalyzed cyclosporine metabolism by glyburide. Since the inhibitory potential of glyburide on CYP3A4 is weak compared with that of other CYP3A4 inhibitors [e.g., ketoconazole (K i ϭ 0.015 M), itraconazole (K i ϭ 0.27 M), fluconazole (K i ϭ 1.27 M)] (von Moltke et al., 1996; Gibbs et al., 1999) , the mechanism that causes drug interactions might not be related to direct inhibition by glyburide. Further evaluation of the exact mechanism of the interaction between these two drugs is needed.
In conclusion, this study demonstrated that glyburide is a potent inhibitor of CYP2C9 and a weak inhibitor of CYP3A4. However, the other P450s tested (CYP1A2, 2C8, 2C19, 2E1, and 2D6) were not affected by glyburide. The inhibition of CYP2C9 seems to explain the observed drug interaction of glyburide with warfarin. It is anticipated that clinically significant drug-drug interactions will likely ensue when glyburide is coadministered with agents having narrow therapeutic ranges that are cleared primarily by CYP2C9-mediated pathways.
